Biopharmaceutical company TNF Pharmaceuticals Inc (Nasdaq: TNFA) announced on Wednesday that it presented its oral TNF-alpha inhibitor isomyosamine during a platform presentation titled "Isomyosamine for the Treatment of Sarcopenia in Older Adults" at the British Geriatrics Society Spring Meeting, held 09–11 April 2025 in Belfast, Ireland and online.
Mitchell Glass, MD, President and Chief Medical Officer, outlined positive clinical data that validate the start of a larger Phase 2b trial in elderly patients post-hip fracture.
Data indicate that isomyosamine decreases biomarkers associated with TNF-alpha activation in elderly patients with sarcopenia.
Glass reaffirmed the company's commitment to addressing sarcopenia, including muscle wasting associated with GLP-1 agonist treatments, and noted plans to extend Phase 3 trials into the UK and Europe.
Isomyosamine, a novel plant alkaloid (ICD-10-CM code M62.84), regulates the immuno-metabolic system by modulating pro-inflammatory cytokines such as TNF-alpha. TNF Pharmaceuticals remains dedicated to developing innovative therapies that extend healthy lifespan and address autoimmune and inflammatory conditions.
Cinclus Pharma signs EUR220m European commercialisation deal with Zentiva for acid reflux therapy
Sanofi to acquire Vigil Neuroscience for USD470m to expand Alzheimer's pipeline
Moderna withdraws application for flu-COVID combination vaccine pending additional efficacy data
Revalesio reports further analysis from Phase 2 RNS60 trial for acute ischemic stroke treatment
AnnJi reports positive Phase 1/2a results in Spinal and Bulbar Muscular Atrophy trial
Sarepta receives UK approval to continue dosing in ELEVIDYS ENVISION study
MSD expands clinical development of Orion's opevesostat to include women's cancers
Promontory Therapeutics reports successful FDA meeting after Phase 2 study of PT-112
Trevi Therapeutics reports additional results from Phase 2a RIVER trial of Haduvio
Accropeutics reports positive data from Phase 2 psoriasis treatment trial
NextCell Pharma partners with Fujifilm Irvine Scientific to deliver integrated MSC solutions
Lifecare files for first human trial of glucose monitoring implant, targeting CE-mark
EXACT Therapeutics reports strong Phase 1 results for ACTIVATE trial in colorectal liver metastases